Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition with an increasing prevalence, largely driven by rising rates of obesity, metabolic syndrome, and type 2 diabetes. Pharmacological treatments exist for MASLD to help manage weight and blood glucose levels.
The US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that up to 40% of patients attending hepatology clinics use some form of dietary bioactive substances in addition to their pharmacological treatments. Examples of dietary bioactive substances of public interest for MASLD include Curcumin (Turmeric), Silymarin (Milk Thistle), Resveratrol, and Coffee and Green Tea polyphenols.
As part of its Bioactives Thought Leadership Initiative, Brightseed funded a scoping review with the aim of identifying and characterizing the current evidence on dietary bioactive-substance-based interventions for adults, 18 years of age or older, with MASLD to help inform research and future development of randomized controlled trials (RCTs) and systematic reviews (SRs) in this area.
According to Dr. Taylor Wallace, CEO at Think Healthy Group, LLC, adjunct associate professor in the School of Medicine and Health Sciences at George Washington University, and an esteemed member of Brightseed’s Bioactives Coalition, “This valuable research offers key insights into the extent of evidence surrounding how some bioactives may effect MASLD and highlights the great need for additional research on specific bioactives that have potential to benefit consumers.”
Brightseed is grateful to the authors from the Academy of Nutrition and Dietetics for their collaboration on this project. The scoping review is published in the Journal of Nutrients.
Dr. Swati Kalgaonkar
Head of Medical, Scientific and Regulatory Affairs
Brightseed
